ArticleUrolithiasis2025
A phase I efficacy study of ureteroscopy-assisted flexible negative pressure Suction sheath in the treatment of renal stones larger than 4 cm.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the feasibility, safety, and efficacy attributes of one-stage treatment of ≥ 4 cm renal stones using flexible ureteroscopy (FURS)-assisted head-end flexible negative pressure suction sheath (TFS-UAS). Initially, we retrospectively analyzed the samples from a total of 161 patients with renal stones (≥ 4 cm) who underwent surgical treatment at the Department of Urology of the First Affiliated Hospital of Fujian Medical University from October 2022 to November 2024. Accordingly, the subjects were initially divided into minimally invasive percutaneous nephrolithotripsy (mPNL, n = 80) and TFS-UAS-combined FURS lithotripsy (TFS-UAS, n = 81) groups. Further, the demographic characteristics, laboratory tests, stone parameters, surgical information, SFR, and perioperative complications were analyzed. The findings showed no statistically significant differences in demographic characteristics, inflammatory indicators, changes in serum creatinine (Scr) and glomerular filtration rate (GFR), maximum stone diameter, maximum width, CT values, and degree of hydronephrosis between the two groups. The one-stage complete stone-free rate (SFR) in the TFS-UAS group (49.4% vs. 20.0%) (P < 0.001) and relative SFR (61.7% vs. 45.0%) (P = 0.033) were significantly higher in the TFS-UAS group than in the mPNL group. After phase II treatment, the complete SFR (65.4% vs. 46.3%, P = 0.014) and relative SFR (75.3% vs. 58.8%, P = 0.025) in the TFS-UAS group were still significantly higher than those in the mPNL group of patients. The TFS-UAS-combined FURS method effectively treated kidney stones (≥ 4 cm) during phase I. Nevertheless, further investigations are required to explore postoperative infections.
Indexed as
Identifiers
40445241What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.